Georgia's Online Cancer Information Center

Gynecologic Cancers Clinical Trials in Georgia

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.
Cancer Type = Gynecologic Cancers
Cancer Type = Gynecologic Cancers
There are currently 13 active Gynecologic Cancers clinical trials in Georgia.
1.
A Study Combining the Peposertib (M3814) Pill with Standard Chemotherapy in Patients with Ovarian Cancer with an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer
Cancer Type
Gynecologic Cancers, Ovarian Cancer, Primary Peritoneal Cancer
NCT ID
NCT04092270
Protocol IDs
10324
10324
NCI-2019-06123
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
2.
A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
Cancer Type
Gynecologic Cancers, Ovarian Cancer, Primary Peritoneal Cancer
NCT ID
NCT06072781
Protocol IDs
VS-6766-301
NCI-2024-00300
ENGOT-ov81
GOG-3097
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
3.
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
Cancer Type
Esophogeal Cancer, Gynecologic Cancers, Lung Cancer, Ovarian Cancer, Prostate Cancer
NCT ID
NCT06238479
Protocol IDs
LOXO-ENC-23001
NCI-2024-02612
2023-509867-26-00
J5A-OX-JZWA
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
4.
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRa)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Cancer Type
Gynecologic Cancers, Lung Cancer, Ovarian Cancer, Primary Peritoneal Cancer, Solid Tumor
NCT ID
NCT04300556
Protocol IDs
MORAb-202-G000-201
NCI-2020-06147
2019-003600-12
5.
Evaluation of Sexual Toxicities in Women After Pelvic Radiotherapy
Cancer Type
Anal Cancer, Cervical Cancer, Colon/Rectal Cancer, Gynecologic Cancers, Solid Tumor, Uterine Cancer
NCT ID
NCT05394428
Protocol IDs
20-2369
NCI-2022-05850
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
6.
Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Cancer Type
Gynecologic Cancers, Ovarian Cancer, Primary Peritoneal Cancer, Unknown Primary
NCT ID
NCT05659381
Protocol IDs
GOG-3068
NCI-2023-08813
217908
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
7.
NCORP Trial
Letrozole with or without Paclitaxel and Carboplatin in Treating Patients with Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Cancer Type
Gynecologic Cancers, Ovarian Cancer, Primary Peritoneal Cancer, Unknown Primary
NCT ID
NCT04095364
Protocol IDs
NRG-GY019
NRG-GY019
NCI-2019-01460
Treatment Sites (4)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
City of Hope Atlanta
Newnan
Brian Wortz, PharmD, ACRP-CP
770-400-6169
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
8.
Message-Based Communication Outreach Intervention in Engaging Ovarian Cancer Survivors and Relatives to Consider Genetic Screening Services
Cancer Type
Gynecologic Cancers, Ovarian Cancer, Primary Peritoneal Cancer, Unknown Primary
NCT ID
NCT04927013
Protocol IDs
RSPH4984-20
NCI-2020-02281
STUDY00000224
9.
NCORP Trial
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA)
Cancer Type
Gynecologic Cancers, Ovarian Cancer, Primary Peritoneal Cancer, Unknown Primary
NCT ID
NCT05445778
Protocol IDs
IMGN853-0421
NCI-2023-00369
Treatment Sites (1)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
10.
NCORP Trial
Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer
Cancer Type
Gynecologic Cancers, Ovarian Cancer, Primary Peritoneal Cancer, Unknown Primary
NCT ID
NCT05257408
Protocol IDs
CORT125134-556
NCI-2022-07960
GOG-3073
Treatment Sites (2)
Northeast Georgia Medical Center - Gainesville
Gainesville
Trena Davis
770-219-8822
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
11.
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)
Cancer Type
Colon/Rectal Cancer, Gynecologic Cancers
NCT ID
NCT02628067
Protocol IDs
NCT02628067
3475-158
2015-002067-41
163196
Treatment Sites (3)
12.
Targeted Therapy Directed by Genetic Testing in Treating Patients with Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Cancer Type
Gynecologic Cancers, Ovarian Cancer, Primary Peritoneal Cancer
NCT ID
NCT05564377
Protocol IDs
EAY191
EAY191
NCI-2022-06842
13.
Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer
Cancer Type
Gynecologic Cancers, Ovarian Cancer, Primary Peritoneal Cancer, Unknown Primary
NCT ID
NCT05276973
Protocol IDs
NRG-GY027
NRG-GY027
NCI-2022-01930
Treatment Sites (1)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430